OtherOpen Access
A 2x2 factorial, randomised, open-label trial to determine the clinical and cost- effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: A protocol for the CLEAR clinical trial
Authors
Author Affiliations
Queen's University Belfast, University of Ulster, Belfast Health and Social Care Trust, University Hospital Southampton NHS Foundation Trust, ...
Published InResearch Square
Year2019
Abstract
Abstract Background: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum-removal as part of standard care. We hypothesise that mucoactive agents (HTS or cabocisteine, or a combination) are effective in reducing exacerbations over a 52-week period, compared to usual care. Methods: A 52-week, 2x2 factorial randomised open label trial to determine the clinical and cost-effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care: CLEAR ( cl inical and cost- e ffectiveness of hypertonic saline (HTS 6%) and carbocisteine for a irway clea r ance versus usual care). Patients will be randomised to either (i) Standard care and twice daily…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.